Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 63 results for dyspepsia

  1. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support. We have also published a guideline on postnatal care , which covers the topics of emotional attachment and baby feeding.

  2. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  3. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

  4. The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)

    This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]

  5. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  6. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

  7. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

  8. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  9. Stretta System for gastro-oesophageal reflux disease (MIB74)

    NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease

  10. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

  11. Dementia. Patient decision aid on enteral (tube) feeding for people living with severe dementia

    there are treatable reasons for the person's loss of appetite (such as indigestion, constipation or a sore mouth) these should be...

  12. Colorectal cancer . Patient decision aid on Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer?

    possible side effects of aspirin? The most common side effects include indigestion, bruising more easily and cuts taking longer to stop...

  13. Bisphosphonates for treating osteoporosis. Patient decision aid on bisphosphonates for treating osteoporosis

    bisphosphonate treatment? The most common side effects include: : heartburn and indigestion : pain or stiffness in your muscles, joints...

  14. Coeliac disease: recognition, assessment and management (NG20)

    This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

  15. Actim Pancreatitis for diagnosing acute pancreatitis (MIB218)

    NICE has developed a medtech innovation briefing (MIB) on Actim Pancreatitis for diagnosing acute pancreatitis .